28286285|t|Minocycline reduces mechanical allodynia and depressive-like behaviour in type-1 diabetes mellitus in the rat
28286285|a|A common and devastating complication of diabetes mellitus is painful diabetic neuropathy (PDN) that can be accompanied by emotional disorders such as depression. A few studies have suggested that minocycline that inhibits microglia may attenuate pain hypersensitivity in PDN. Moreover, a recent study reported that minocycline has an acute antidepressive-like effect in diabetic animals. Here we studied whether (i) prolonged minocycline treatment suppresses pain behaviour in PDN, (ii) the minocycline effect varies with submodality of pain, and (iii) the suppression of pain behaviour by prolonged minocycline treatment is associated with antidepressive-like effect. The experiments were performed in streptozotocin - induced rat model of type-1 diabetes. Pain behaviour was evoked by innocuous (monofilaments) and noxious (paw pressure) mechanical stimulation, innocuous cold (acetone drops) and noxious heat (radiant heat). Depression-like behaviour was assessed using forced swimming test. Minocycline treatment (daily 80 mg/kg per os) of three- week duration started four weeks after induction of diabetes. Diabetes induced mechanical allodynia and hyperalgesia, cold allodynia, heat hypoalgesia, and depression-like behaviour. Minocycline treatment significantly attenuated mechanical allodynia and depression-like behaviour, while it failed to produce significant changes in mechanical hyperalgesia, cold allodynia or heat hypoalgesia. The results indicate that prolonged per oral treatment with minocycline has a sustained mechanical antiallodynic and antidepressive-like effect in PDN. These results support the proposal that minocycline might provide a treatment option for attenuating sensory and comorbid emotional symptoms in chronic PDN.
28286285	0	11	Minocycline	T109,T195	C0026187
28286285	12	19	reduces	T080	C0392756
28286285	20	40	mechanical allodynia	T184	C2936719
28286285	45	70	depressive-like behaviour	T048	C0011570
28286285	74	98	type-1 diabetes mellitus	T047	C0011854
28286285	106	109	rat	T015	C0034693
28286285	135	147	complication	T046	C0544688
28286285	151	168	diabetes mellitus	T047	C0011854
28286285	172	199	painful diabetic neuropathy	T047	C0751074
28286285	201	204	PDN	T047	C0751074
28286285	233	252	emotional disorders	T048	C0233459
28286285	261	271	depression	T048	C0011570
28286285	307	318	minocycline	T109,T195	C0026187
28286285	324	332	inhibits	T052	C3463820
28286285	333	342	microglia	T025	C0206116
28286285	347	356	attenuate	T052	C0599946
28286285	357	378	pain hypersensitivity	T184	C1405033
28286285	382	385	PDN	T047	C0751074
28286285	426	437	minocycline	T109,T195	C0026187
28286285	445	477	acute antidepressive-like effect	T184	C1457887
28286285	481	497	diabetic animals	T008	C0003062
28286285	527	536	prolonged	T079	C0439590
28286285	537	548	minocycline	T109,T195	C0026187
28286285	549	558	treatment	T169	C1522326
28286285	559	569	suppresses	T169	C1260953
28286285	570	584	pain behaviour	T055	C0946267
28286285	588	591	PDN	T047	C0751074
28286285	602	613	minocycline	T109,T195	C0026187
28286285	614	620	effect	T080	C1280500
28286285	633	652	submodality of pain	T184	C0030193
28286285	668	679	suppression	T169	C1260953
28286285	683	697	pain behaviour	T055	C0946267
28286285	701	710	prolonged	T079	C0439590
28286285	711	722	minocycline	T109,T195	C0026187
28286285	723	732	treatment	T061	C0087111
28286285	736	751	associated with	T080	C0332281
28286285	752	778	antidepressive-like effect	T184	C1457887
28286285	784	795	experiments	T062	C0205664
28286285	814	828	streptozotocin	T109,T195	C0038432
28286285	831	838	induced	T169	C0205263
28286285	839	842	rat	T015	C0034693
28286285	843	848	model	T008	C0599779
28286285	852	867	type-1 diabetes	T047	C0011854
28286285	869	883	Pain behaviour	T055	C0946267
28286285	909	922	monofilaments	T074	C1658323
28286285	937	949	paw pressure	T201	C4298860
28286285	951	973	mechanical stimulation	T061	C1285354
28286285	975	989	innocuous cold	T047	C0009443
28286285	991	998	acetone	T109,T121	C0001002
28286285	991	1004	acetone drops	T122	C0991568
28286285	1010	1022	noxious heat	T070	C0018837
28286285	1024	1036	radiant heat	T070	C0563232
28286285	1039	1064	Depression-like behaviour	T048	C0011570
28286285	1069	1077	assessed	T052	C1516048
28286285	1084	1104	forced swimming test	T060	C0683444
28286285	1106	1117	Minocycline	T109,T195	C0026187
28286285	1118	1127	treatment	T169	C1522326
28286285	1138	1150	mg/kg per os	T169	C1527415
28286285	1162	1166	week	T079	C0439230
28286285	1167	1175	duration	T079	C0449238
28286285	1189	1194	weeks	T079	C0439230
28286285	1201	1210	induction	T169	C0205263
28286285	1214	1222	diabetes	T047	C0011847
28286285	1224	1232	Diabetes	T047	C0011847
28286285	1233	1240	induced	T169	C0205263
28286285	1241	1261	mechanical allodynia	T184	C2936719
28286285	1266	1278	hyperalgesia	T184	C0020429
28286285	1280	1294	cold allodynia	T033	C0458247
28286285	1296	1312	heat hypoalgesia	T184	C0085625
28286285	1318	1343	depression-like behaviour	T048	C0011570
28286285	1345	1356	Minocycline	T109,T195	C0026187
28286285	1357	1366	treatment	T061	C0087111
28286285	1381	1391	attenuated	T052	C0599946
28286285	1392	1412	mechanical allodynia	T184	C2936719
28286285	1417	1442	depression-like behaviour	T048	C0011570
28286285	1453	1459	failed	T169	C0231175
28286285	1494	1517	mechanical hyperalgesia	T184	C2936719
28286285	1519	1533	cold allodynia	T033	C0458247
28286285	1537	1553	heat hypoalgesia	T184	C0085625
28286285	1581	1590	prolonged	T079	C0439590
28286285	1591	1609	per oral treatment	T169	C1527415
28286285	1615	1626	minocycline	T109,T195	C0026187
28286285	1633	1642	sustained	T169	C0443318
28286285	1643	1667	mechanical antiallodynic	T184	C1457887
28286285	1672	1698	antidepressive-like effect	T184	C1457887
28286285	1702	1705	PDN	T047	C0751074
28286285	1747	1758	minocycline	T109,T195	C0026187
28286285	1775	1791	treatment option	T061	C0683525
28286285	1796	1807	attenuating	T052	C0599946
28286285	1808	1847	sensory and comorbid emotional symptoms	T184	C1396398
28286285	1851	1862	chronic PDN	T047	C0393830